相关实验视频

Updated: Apr 12, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

慢性HBV患者的短期基化干扰素α与超低HBsAg:一个回顾性研究

Huimin Liu¹, Hongmei Gong¹, Zhaoxia Tan¹

¹Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Infectious Disease Research of Chongqing, Infectious Disease Clinical Research Center of Chongqing, Chongqing, China.

Frontiers in cellular and infection microbiology

|September 22, 2025

概括

短期基化干扰素α (Peg-IFNα) 治疗显著增加了慢性乙型肝炎患者的乙型肝炎表面抗原 (HBsAg) 清除,这些患者的HBsAg水平非常低,这为功能治愈提供了有希望的策略.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
免疫学免疫学免疫学

背景情况:

乙型肝炎表面抗原 (HBsAg) 清除对于在慢性乙型肝炎 (CHB) 中实现功能治愈至关重要.
超低HBsAg水平 (<50 IU/ml) 的患者代表了强化治疗策略的目标人群.
核酸类比 (NUC) 治疗是标准的,但HBsAg清除仍然具有挑战性.

研究的目的:

评估短期基化干扰素α (Peg-IFNα) 在实现HBsAg清除方面的疗效.
评估Peg-IFNα在患有超低HBsAg水平的CHB患者中的有效性,包括NUC治疗和不活跃的HBsAg载体 (IHCs).

主要方法:

总共有378名HBsAg<50 IU/ml的CHB患者被纳入.
队列包括接受NUC治疗的患者 (有或没有Peg-IFNα补充剂) 和IHC (有或没有Peg-IFNα).
主要终点是24周的HBsAg清除率.

主要成果:

24周的HBsAg清除率为69.88% (NUC添加Peg-IFNα) 和55.81% (Peg-IFNα组),明显高于对照组的零 (p < 0.001).
基线HBsAg<10 IU/ml的患者表现出更高的清除率.
在第12周HBsAg下降≥95.8%,预测第24周清除 (AUC≥0.9).

结论:

短期Peg-IFNα治疗有效地实现了高的HBsAg清除率.
这种方法对接受NUC治疗的患者和具有超低HBsAg水平的IHC有希望.
早期的HBsAg下降预测了成功的清除,指导治疗决策.

关键词:

在HBsAg清除过程中,慢性乙型肝炎慢性乙型肝炎基化干扰素干扰素是什么?这是短期治疗.超低的表面抗原水平.

更多相关视频

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

相关概念视频

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...